CD73 on cancer-associated fibroblasts enhanced by the A<sub>2B</sub>-mediated feedforward circuit enforces an immune checkpoint.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31980601.
- Also identified by DOI 10.1038/s41467-019-14060-x and PMC identifier 6981126.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
CD73, an ecto-5'-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A<sub>2A</sub> receptor. Elevated CD73 levels in tumor tissues correlate with poor clinical outcomes. However, the crucial source of CD73 activity within the tumor microenvironment remains unspecified. Here, we demonstrate that cancer-associated fibroblasts (CAFs) constitute the prominent CD73<sup>hi</sup> population in human colorectal cancers (CRCs) and two CD73<sup>-</sup> murine tumor models, including a modified CRC. Clinically, high CAF abundancy in CRC tissues correlates strongly with elevated CD73 activity and poor prognosis. Mechanistically, CAF-CD73 expression is enhanced via an ADO-A<sub>2B</sub> receptor-mediated feedforward circuit triggered by tumor cell death, which enforces the CD73-checkpoint. Simultaneous inhibition of A<sub>2A</sub> and A<sub>2B</sub> pathways with CD73-neutralization synergistically enhances antitumor immunity in CAF-rich tumors. Therefore, the strategic and effective targeting of both the A<sub>2B</sub>-mediated ADO-CAF-CD73 feedforward circuit and A<sub>2A</sub>-mediated immune suppression is crucial for improving therapeutic outcomes.
Medical subject headings
- 5'-Nucleotidase
- Cancer-Associated Fibroblasts
- Colorectal Neoplasms
- Receptor, Adenosine A2B